Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: Long-term follow-up of CALGB study 9712

Journal of Clinical Oncology

Volumn 29, Issue 10, 2011, Pages 1349-1355

  Woyach, Jennifer A ^{a,b,c,d,e,f,g}   Ruppert, Amy S ^{a,b,c,d,e,f,g}   Heerema, Nyla A ^{a,b,c,d,e,f,g}   Peterson, Bercedis L ^{a,b,c,d,e,f,g}   Gribben, John G ^{a,b,c,d,e,f,g}   Morrison, Vicki A ^{a,b,c,d,e,f,g}   Rai, Kanti R ^{a,b,c,d,e,f,g}   Larson, Richard A ^{a,b,c,d,e,f,g}   Byrd, John C ^{a,b,c,d,e,f,g}  

^a OHIO STATE UNIVERSITY   (United States)

^b DUKE UNIVERSITY   (United States)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d UNIVERSITY OF MINNESOTA   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^g UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; HEMOGLOBIN; IMMUNOGLOBULIN HEAVY CHAIN; LACTATE DEHYDROGENASE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CYTOGENETICS; DISEASE COURSE; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC RISK; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LEUKOCYTE COUNT; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTOGENETIC ANALYSIS; DISEASE-FREE SURVIVAL; GENES, IMMUNOGLOBULIN HEAVY CHAIN; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LEUKEMIA, MYELOID, ACUTE; LONDON; MUTATION; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; VIDARABINE;

EID: 79954435811     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.31.1811     Document Type: Article

References (31)

1. Rai KR, Peterson BL, Appelbaum FR, et al: Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 343:1750-1757, 2000
2. Johnson S, Smith AG, Löffler H, et al: Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advancedstage chronic lymphocytic leukaemia: The French Cooperative Group on CLL. Lancet 347:1432-1438, 1996 (Pubitemid 26161205)
3. Leporrier M, Chevret S, Cazin B, et al: Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 98:2319-2325, 2001
4. Eichhorst BF, Busch R, Stilgenbauer S, et al: First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 114:3382-3391, 2009
5. Rai K, Peterson BL, Appelbaum FR, et al: Long-term survival analysis of the north american intergroup study c9011 comparing fludarabine and chlorambucil in previously untreated patients with chronic lymphocytic leukemia. Blood 114:536, 2009 (abstr 536)
6. Flinn IW, Neuberg DS, Grever MR, et al: Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol 25:793-798, 2007 (Pubitemid 350002879)
7. Catovsky D, Richards S, Matutes E, et al: Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): A randomised controlled trial. Lancet 370:230-239, 2007 (Pubitemid 47069536)
8. Eichhorst BF, Busch R, Hopfinger G, et al: Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 107:885-891, 2006 (Pubitemid 43156283)
9. Hainsworth JD, Litchy S, Barton JH, et al: Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: A phase II trial of the Minnie Pearl Cancer Res Network. J Clin Oncol 21:1746-1751, 2003 (Pubitemid 46638587)
10. Itä lä M, Geisler CH, Kimby E, et al: Standarddose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: Results from a Nordic multicentre study. Eur J Haematol 69:129-134, 2002 (Pubitemid 35335149)
11. McLaughlin P, Grillo-López AJ, Link BK, et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998 (Pubitemid 28363048)
12. Byrd JC, Murphy T, Howard RS, et al: Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 19:2153-2164, 2001 (Pubitemid 32366969)
13. O'Brien SM, Kantarjian H, Thomas DA, et al: Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 19:2165-2170, 2001 (Pubitemid 32366970)
14. Byrd JC, Peterson BL, Morrison VA, et al: Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: Results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 101:6-14, 2003 (Pubitemid 36025880)
15. Schulz H, Klein SK, Rehwald U, et al: Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood 100:3115-3120, 2002 (Pubitemid 35217057)
16. Keating MJ, O'Brien S, Albitar M, et al: Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23:4079-4088, 2005 (Pubitemid 46211313)
17. Stilgenbauer S, Zenz T, Winkler D, et al: Genomic aberrations, VH mutation status and outcome after fludarabine and cyclophosphamide (FC) or FC plus rituximab (FCR) in the CLL8 trial. Blood 112:781, 2008 (abstr 781)
18. Hallek M, Fischer K, Fingerle-Rowson G, et al: Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial. Lancet 376:1164-1174, 2010
19. Tam CS, O'Brien S, Wierda W, et al: Longterm results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 112:975-980, 2008
20. Cheson BD, Bennett JM, Grever M, et al: National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 87:4990-4997, 1996 (Pubitemid 26189840)
21. Byrd JC, Gribben JG, Peterson BL, et al: Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: Justification for risk-adapted therapy. J Clin Oncol 24:437-443, 2006 (Pubitemid 46655595)
22. Hallek M, Cheson BD, Catovsky D, et al: Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111:5446-5456, 2008
23. Morrison VA, Rai KR, Peterson BL, et al: Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: Results of an intergroup study, cancer and leukemia group B 9011. J Clin Oncol 20:3878-3884, 2002
24. Morrison VA: In reply to: Fludarabine-related myeloid leukemia. J Clin Oncol 21:3709-3710, 2003
25. Lam CC, Ma ES, Kwong YL: Therapy-related acute myeloid leukemia after single-agent treatment with fludarabine for chronic lymphocytic leukemia. Am J Hematol 79:288-290, 2005 (Pubitemid 41098841)
26. Byrd JC, Rai K, Peterson BL, et al: Addition of rituximab to fludarabine may prolong progressionfree survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: An updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 105:49-53, 2005 (Pubitemid 40053062)
27. Sutton L, Chevret S, Maloum K, et al: Autologous stem cell transplantation (ASCT) in CLL. results of a phase III randomized multicenter trial. Blood: 878, 2009 (abstr 878)
28. Gribben JG, Zahrieh D, Stephans K, et al: Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood 106:4389-4396, 2005 (Pubitemid 41775953)
29. Moreton P, Kennedy B, Lucas G, et al: Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 23:2971-2979, 2005 (Pubitemid 46224116)
30. Kwok MRA, Varghese A, Hillmen P: Minimal residual disease is a predictor for progression-free and overall survival in chronic lymphocytic leukemia (CLL) that is independent of the type or line of therapy. Blood 114:540, 2009 (abstr 540)
31. Tsimberidou AM, Tam C, Abruzzo LV, et al: Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia. Cancer 115:373-380, 2009